LumiSTAR Biotechnology, Inc.
Update：2026/03/31
Industries
Main Industry
Biotechnology
Main Product/Service
1. IPSC
2. LumiRDT
2. LumiRDT
Founded Year
2016
Unified Business No.
52485407
Status
Active
Number of Employees
0
Total Paid-in
Capital
16,065,040 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
LumiSTAR is developing a pipeline of innovative cell therapies based on induced pluripotent stem cell (iPSC) technology. These therapies have the potential to revolutionize the treatment of a wide range of diseases, including neurodegenerative diseases such as Parkinson’s and Alzheimer’s, CKD and cancer.
Other than cell therapy, the company also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates.
Other than cell therapy, the company also equipped with iPSC and bioimaging-based high throughput drug screening platform to develop new drugs. The platform uses iPSC to create disease models for drug discovery and screening, allowing for more accurate and efficient identification of potential drug candidates.
